CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Ribo y Boehringer Ingelheim siguen avanzando en su programa de siRNA

PartnershipPositive
AI Analysis

Summary

Ribo and Boehringer Ingelheim continue advancing their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH). The article announces ongoing progress in their collaborative development effort.

Importance:5/10
Sentiment:
0.30
siRNAMASHPartnershipLiver disease
Related Companies

Read the original article

Published by PR Newswire Pharma on May 6, 2026 3:14 PM

Read Original